Literature DB >> 10768923

Binding to and opsonophagocytic activity of O-antigen-specific monoclonal antibodies against encapsulated and nonencapsulated Klebsiella pneumoniae serotype O1 strains.

T K Held1, N R Jendrike, T Rukavina, R Podschun, M Trautmann.   

Abstract

The high mortality of nosocomial infections caused by Klebsiella spp. has acted as a stimulus to develop immunotherapeutic approaches targeted against surface molecules of these bacteria. Since O-antigen-specific antibodies may add to the protective effect of K antisera, we tested the functional and binding capacity of O-antigen-specific monoclonal antibodies (MAbs) raised against different Klebsiella O antigens. The MAbs tested were specific for the O-polysaccharide partial antigens D-galactan II (MAb Ru-O1), D-galactan I (MAb IV/4-5), or core oligosaccharide (MAb V/9-5) of the Klebsiella serogroup O1 antigen. In enzyme-linked immunosorbent assay binding experiments, we found that all MAbs recognized their epitopes on intact capsule-free bacteria; however, binding to encapsulated wild-type strains belonging to different K-antigen serotypes was significantly reduced. The K2 antigen acted as the strongest penetration barrier, while the K7 and K21 antigens allowed some, though diminished, antibody binding. In vitro phagocytic killing experiments showed that MAb Ru-O1 possessed significant opsonizing activity for nonencapsulated O1 serogroup strains and also, to a much lesser extent, for encapsulated strains belonging to the O1:K7 and O1:K21 serotypes. MAbs or antisera specific for the D-galactan II antigen may thus be the most promising agents for further efforts to develop a second-generation Klebsiella hyperimmune globulin comprising both K- and O-antigen specificities.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768923      PMCID: PMC97438          DOI: 10.1128/IAI.68.5.2402-2409.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  58 in total

1.  Immunoenzymatic analysis by monoclonal antibodies of bacterial lipopolysaccharides after transfer to nitrocellulose.

Authors:  H Sidberry; B Kaufman; D C Wright; J Sadoff
Journal:  J Immunol Methods       Date:  1985-02-11       Impact factor: 2.303

2.  In vitro and in vivo activities of different immunoglobulin G preparations from the rabbit against Enterobacteriaceae.

Authors:  M Trautmann; Y Müller-Leutloff; T Hofstaetter; F R Seiler; H Hahn
Journal:  Vox Sang       Date:  1985       Impact factor: 2.144

3.  Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group.

Authors:  S T Donta; P Peduzzi; A S Cross; J Sadoff; C Haakenson; S J Cryz; C Kauffman; S Bradley; G Gafford; D Elliston; T R Beam; J F John; B Ribner; R Cantey; C H Welsh; R T Ellison; E J Young; R J Hamill; H Leaf; R M Schein; M Mulligan; C Johnson; E Abrutyn; J M Griffiss; D Slagle
Journal:  J Infect Dis       Date:  1996-09       Impact factor: 5.226

4.  Purification and vaccine potential of Klebsiella capsular polysaccharides.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

Review 5.  Changing etiology of nosocomial bacteremia and fungemia and other hospital-acquired infections.

Authors:  J E McGowan
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

6.  The role of the O and K antigens in determining the resistance of Klebsiella aerogenes to serum killing and phagocytosis.

Authors:  P Williams; P A Lambert; M R Brown; R J Jones
Journal:  J Gen Microbiol       Date:  1983-07

7.  Effect of subinhibitory concentrations of cephalosporins on surface properties and siderophore production in iron-depleted Klebsiella pneumoniae.

Authors:  J L Kadurugamuwa; H Anwar; M R Brown; O Zak
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

8.  The distribution of Klebsiella pneumoniae serotypes from different sources and their sensitivity to cephalosporins.

Authors:  U Ullmann
Journal:  Infection       Date:  1983       Impact factor: 3.553

9.  Mechanism of priming of human neutrophils by a soluble lymphoblastoid cell factor.

Authors:  A S Cross; G H Lowell; J Palmblad; J C Sadoff; L Young; M Berger
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

Review 10.  The epidemiology of nosocomial infections caused by Klebsiella pneumoniae.

Authors:  W R Jarvis; V P Munn; A K Highsmith; D H Culver; J M Hughes
Journal:  Infect Control       Date:  1985-02
View more
  7 in total

1.  Role of neutrophils in response to Bordetella pertussis infection in mice.

Authors:  Charlotte Andreasen; Nicholas H Carbonetti
Journal:  Infect Immun       Date:  2008-12-22       Impact factor: 3.441

2.  Lipopolysaccharide-mediated protection against Klebsiella pneumoniae-induced lobar pneumonia: intranasal vs. intramuscular route of immunization.

Authors:  V Yadav; S Sharma; K Harjai; H Mohan; S Chhibber
Journal:  Folia Microbiol (Praha)       Date:  2005       Impact factor: 2.629

3.  Proinflammatory cytokines in antilipopolysaccharide immunity against Klebsiella infections.

Authors:  Tomislav Rukavina; Vanja Vasiljev; Brigita Ticac
Journal:  Mediators Inflamm       Date:  2005-06-09       Impact factor: 4.711

4.  Discovery of monoclonal antibodies cross-reactive to novel subserotypes of K. pneumoniae O3.

Authors:  Luis M Guachalla; Katarina Stojkovic; Katharina Hartl; Marta Kaszowska; Yadhu Kumar; Benjamin Wahl; Tobias Paprotka; Eszter Nagy; Jolanta Lukasiewicz; Gábor Nagy; Valéria Szijártó
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

5.  Variation in Cell Surface Hydrophobicity among Cryptococcus neoformans Strains Influences Interactions with Amoebas.

Authors:  Raghav Vij; Carina Danchik; Conor Crawford; Quigly Dragotakes; Arturo Casadevall
Journal:  mSphere       Date:  2020-04-29       Impact factor: 4.389

6.  IL-10 in antilipopolysaccharide immunity against systemic Klebsiella infections.

Authors:  Tomislav Rukavina; Brigita Ticac; Vanja Vasiljev
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

7.  Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa.

Authors:  Nicolas Hegerle; Myeongjin Choi; James Sinclair; Mohammed N Amin; Morgane Ollivault-Shiflett; Brittany Curtis; Rachel S Laufer; Surekha Shridhar; Jerod Brammer; Franklin R Toapanta; Ian Alan Holder; Marcela F Pasetti; Andrew Lees; Sharon M Tennant; Alan S Cross; Raphael Simon
Journal:  PLoS One       Date:  2018-09-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.